Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation

Bone Marrow Transplant. 2019 Jul;54(7):1158-1160. doi: 10.1038/s41409-019-0450-3. Epub 2019 Jan 25.

Authors

Michelle Schoettler¹, Christine Duncan², Leslie Lehmann², Elissa Furutani², Meera Subramaniam³, Steven Margossian²

Affiliations

¹ Boston Children's/Dana Farber Cancer and Blood Disorders Center, Boston, MA, USA. [email protected].
² Boston Children's/Dana Farber Cancer and Blood Disorders Center, Boston, MA, USA.
³ Department of Pulmonology, Boston Children's Hospital, Boston, MA, USA.

No abstract available

Publication types

Clinical Trial
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Allografts
Bronchiolitis Obliterans* / drug therapy
Bronchiolitis Obliterans* / etiology
Child
Chronic Disease
Female
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Male
Nitriles
Pyrazoles / administration & dosage*
Pyrazoles / adverse effects
Pyrimidines
Retrospective Studies

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib

Grants and funding